Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

Plasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of advanced non–small-cell lung cancer (NSCLC); however, early response assessment using plasma ctDNA has yet to be well characterized. MATERIALS AND METHODS: Patients with advanced EGFR-mutant NSCLC across three phase I NCI osi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Cheng, Michael L., Lau, Christie J., Milan, Marina S. D., Supplee, Julianna G., Riess, Jonathan W., Bradbury, Penelope A., Jänne, Pasi A., Oxnard, Geoffrey R., Paweletz, Cloud P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2021
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8232122/
https://ncbi.nlm.nih.gov/pubmed/34250387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00419
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars